Back to Journals » Biologics: Targets and Therapy

ESCI
SJR OA
CiteScore
Impact Factor

Biologics: Targets and Therapy

ISSN: 1177-5491


      

Editor-in-Chief: Dr Doris Mangiaracina Benbrook

ISSN: 1177-5475 (Print) - went to online only in 2009

An international, peer reviewed journal focusing on the patho-physiological rationale for, and clinical application of, Biologic agents and their Biosimilars in the management of autoimmune diseases, cancers, or other pathologies where a molecular target can be identified.


This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).

 

 

 

  

 

 

Articles:

Latest articles:

- 5 records -

Review

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer

Zhang Z, Zhang R, Li D

Biologics: Targets and Therapy 2023, 17:113-128

Published Date: 21 September 2023

Review

Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review

Kandula UR, Wake AD

Biologics: Targets and Therapy 2023, 17:85-112

Published Date: 18 May 2023

Original Research

New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells

Długosz-Pokorska A, Perlikowska R, Janecki T, Janecka A

Biologics: Targets and Therapy 2023, 17:69-83

Published Date: 15 May 2023

Case Series

Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience

Percik R, Oedegaard Smith C, Leibovici A, Shai A

Biologics: Targets and Therapy 2023, 17:61-67

Published Date: 3 May 2023

Case report

Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab

Wu C, Zhang J, Zhao Y

Biologics: Targets and Therapy 2023, 17:57-60

Published Date: 20 April 2023


Read more articles